MIT Spin-Off Evaluates Vascular Drug Delivery With $500,000 In VC Funds
This article was originally published in The Gray Sheet
Executive Summary
Pervasis Therapeutics will rely in part on seed money from two Boston venture capital firms to help commercialize a vascular drug delivery device that would promote tissue healing
You may also be interested in...
Financings In Brief
InTouch Health: Santa Barbara, Calif.-based firm will use proceeds from a $12.1 mil. Series C financing for ongoing product development and expansion of its sales and marketing team. The firm recently launched its RP-7 remote presence robotic system. The funding was led by Galen Partners, which will contribute two board members, as well as existing investors Acacia Venture Partners and InvestCare Partners. InTouch founder Yulan Wang previously founded robotics company Computer Motion, which merged with Intuitive Surgical in 2003...
Financings In Brief
InTouch Health: Santa Barbara, Calif.-based firm will use proceeds from a $12.1 mil. Series C financing for ongoing product development and expansion of its sales and marketing team. The firm recently launched its RP-7 remote presence robotic system. The funding was led by Galen Partners, which will contribute two board members, as well as existing investors Acacia Venture Partners and InvestCare Partners. InTouch founder Yulan Wang previously founded robotics company Computer Motion, which merged with Intuitive Surgical in 2003...
Cordis, GenVec Collaborate On Cardiac Drug Delivery Trial To Begin Mid-2004
Intravascular delivery of GenVec's Biobypass angiogenic drug via Johnson & Johnson/Cordis' Myostar catheter will be evaluated in a 125-patient randomized trial featuring a "sham" placebo control